Breaking News

iBio Developing COVID-19 Vaccine Candidates

Several Provisional Patents Filed with USPTO

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

iBio, Inc., a biologics contract manufacturing organization (CMO) and biotechnology company, is progressing towards developing vaccine candidates for preventing infection from the SARS-CoV-2 virus that causes the COVID-19 coronavirus disease.   iBio created its SARS-CoV-2 Virus-Like Particle (VLP)-based constructs in just a few weeks using its FastPharming System to produce the nanoparticles in, and purify them from, plants. The manufacturing platform not only provides for rapid development of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters